-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Enesi Pharmaceuticals of the United Kingdom has signed an agreement with an Australian biotechnology company to develop a solid dose version of the latter's peanut low-dose allergy vaccine and its chikungi/Zika vaccine candidate.
vaccine is being evaluated through Enesi Pharmaceutical Group's ImpalVax technology, needleless solid dose injections to assess the use of the vaccine, and device technology for intrauteric vaccination.
Sementis' research peanut hypoallery vaccine has completed a proof-of-concept study, according to the organization's press release, "provides compelling evidence that it can provide a permanent treatment for peanut allergies."
believes that more than 7 million people in the United States, Europe and Japan suffer from severe peanut allergies, and that a vaccine that supports Impalvax could provide "an easy and effective way to cure peanut allergies on large scales, especially for young patients who may be averse to needles and traditional injections."
Sementis, a single vector vaccine for chikungi/Zika virus infection, also showed promising results in concept validation studies in mice.
"Activate ImplaVax products using the Sementis SCV chikungunya/Zika vaccine provides the potential for long-lasting immunity and can remain effective in a variety of situations," the company said. "Working with our ImpalVax needleless device to develop solid dose versions of these vaccines offers the potential to deliver powerful and effective products that address major global health challenges," said David Hipkiss, Ceo of Enesi. "We are seeing growing interest in the vaccine and public health industries in all regions, depending on the potential benefits that ImpaVax can offer to improve vaccination." "We are very confident that Impravax technology will work with our vaccine vector technology to reduce or even eliminate the cryo-chain environment that relies on maintaining from manufacturing to care points, and may provide long-term stability for our vaccines." Dr Paul Howley, chief executive of Enesi, added.
In addition, Enesi's technology may not require trained health care providers to manage our vaccines because they do not require injections. "We will test this technology with our infectious disease vaccine and one of our allergy vaccines, Candide, and if proven, ImpraVax technology will be suitable for all Smallis vaccines covering infectious diseases, allergies and cancers.
terms of the deal, Enesi will develop solid dose injections based on vaccines provided by Sementis, which will conduct safety and immunogenicity tests, as well as preclinical development. Financial details have not been disclosed. (This web article)